Topical treatment strategies to manipulate human skin pigmentation
Copyright © 2020. Published by Elsevier B.V..
Skin pigmentation is a result of melanin produced by melanocytes in the epidermis. Melanocyte activity, along with the type and distribution of melanins, is the main driver for diversity of skin pigmentation. Dark melanin acts to protect against the deleterious effects of ultraviolet (UV) radiation, including photo-aging and skin cancer formation. In turn, UV radiation activates skin melanocytes to induce further pigmentation (i.e., "tanning pathway"). The well-characterized MSH/MC1R-cAMP-MITF pathway regulates UV-induced melanization. Pharmacologic activation of this pathway ("sunless tanning") represents a potential strategy for skin cancer prevention, particularly in those with light skin or the "red hair" phenotype who tan poorly after UV exposure due to MC1R inactivating polymorphisms. Skin hyperpigmentation can also occur as a result of inflammatory processes and dermatological disorders such as melasma. While primarily of cosmetic concern, these conditions can dramatically impact quality of life of affected patients. Several topical agents are utilized to treat skin pigmentation disorders. Here, we review melanogenesis induced by UV exposure and the agents that target this pathway.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2020 |
---|---|
Erschienen: |
2020 |
Enthalten in: |
Zur Gesamtaufnahme - volume:153 |
---|---|
Enthalten in: |
Advanced drug delivery reviews - 153(2020) vom: 01. Jan., Seite 65-71 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Rachmin, Inbal [VerfasserIn] |
---|
Links: |
---|
Anmerkungen: |
Date Completed 08.09.2021 Date Revised 08.09.2021 published: Print-Electronic Citation Status MEDLINE |
---|
doi: |
10.1016/j.addr.2020.02.002 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM306849887 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM306849887 | ||
003 | DE-627 | ||
005 | 20231225124257.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2020 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1016/j.addr.2020.02.002 |2 doi | |
028 | 5 | 2 | |a pubmed24n1022.xml |
035 | |a (DE-627)NLM306849887 | ||
035 | |a (NLM)32092380 | ||
035 | |a (PII)S0169-409X(20)30008-9 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Rachmin, Inbal |e verfasserin |4 aut | |
245 | 1 | 0 | |a Topical treatment strategies to manipulate human skin pigmentation |
264 | 1 | |c 2020 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 08.09.2021 | ||
500 | |a Date Revised 08.09.2021 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a Copyright © 2020. Published by Elsevier B.V. | ||
520 | |a Skin pigmentation is a result of melanin produced by melanocytes in the epidermis. Melanocyte activity, along with the type and distribution of melanins, is the main driver for diversity of skin pigmentation. Dark melanin acts to protect against the deleterious effects of ultraviolet (UV) radiation, including photo-aging and skin cancer formation. In turn, UV radiation activates skin melanocytes to induce further pigmentation (i.e., "tanning pathway"). The well-characterized MSH/MC1R-cAMP-MITF pathway regulates UV-induced melanization. Pharmacologic activation of this pathway ("sunless tanning") represents a potential strategy for skin cancer prevention, particularly in those with light skin or the "red hair" phenotype who tan poorly after UV exposure due to MC1R inactivating polymorphisms. Skin hyperpigmentation can also occur as a result of inflammatory processes and dermatological disorders such as melasma. While primarily of cosmetic concern, these conditions can dramatically impact quality of life of affected patients. Several topical agents are utilized to treat skin pigmentation disorders. Here, we review melanogenesis induced by UV exposure and the agents that target this pathway | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Research Support, N.I.H., Extramural | |
650 | 4 | |a Research Support, Non-U.S. Gov't | |
650 | 4 | |a Systematic Review | |
650 | 4 | |a MITF | |
650 | 4 | |a Melanocytes | |
650 | 4 | |a Pigmentation | |
650 | 4 | |a cAMP | |
650 | 7 | |a Dermatologic Agents |2 NLM | |
650 | 7 | |a Melanins |2 NLM | |
650 | 7 | |a pheomelanin |2 NLM | |
650 | 7 | |a eumelanin |2 NLM | |
650 | 7 | |a 12627-86-0 |2 NLM | |
650 | 7 | |a Cyclic AMP |2 NLM | |
650 | 7 | |a E0399OZS9N |2 NLM | |
650 | 7 | |a Protein Kinases |2 NLM | |
650 | 7 | |a EC 2.7.- |2 NLM | |
700 | 1 | |a Ostrowski, Stephen M |e verfasserin |4 aut | |
700 | 1 | |a Weng, Qing Yu |e verfasserin |4 aut | |
700 | 1 | |a Fisher, David E |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Advanced drug delivery reviews |d 1995 |g 153(2020) vom: 01. Jan., Seite 65-71 |w (DE-627)NLM086826522 |x 1872-8294 |7 nnns |
773 | 1 | 8 | |g volume:153 |g year:2020 |g day:01 |g month:01 |g pages:65-71 |
856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.addr.2020.02.002 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 153 |j 2020 |b 01 |c 01 |h 65-71 |